ATE211737T1 - Tricyclisch substituierte 2,4-dithi(oxo)- pyrimidin-5-yl-verbindungen als p2- purinoceptor- antagonisten - Google Patents
Tricyclisch substituierte 2,4-dithi(oxo)- pyrimidin-5-yl-verbindungen als p2- purinoceptor- antagonistenInfo
- Publication number
- ATE211737T1 ATE211737T1 AT98934002T AT98934002T ATE211737T1 AT E211737 T1 ATE211737 T1 AT E211737T1 AT 98934002 T AT98934002 T AT 98934002T AT 98934002 T AT98934002 T AT 98934002T AT E211737 T1 ATE211737 T1 AT E211737T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- compounds
- dithi
- pyrimidine
- oxo
- Prior art date
Links
- 239000000423 purinergic P2 receptor antagonist Substances 0.000 title 1
- 229940123344 GPR antagonist Drugs 0.000 abstract 1
- 102000007466 Purinergic P2 Receptors Human genes 0.000 abstract 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702651A SE9702651D0 (sv) | 1997-07-09 | 1997-07-09 | Novel compounds |
| PCT/SE1998/001240 WO1999002501A1 (en) | 1997-07-09 | 1998-06-25 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE211737T1 true ATE211737T1 (de) | 2002-01-15 |
Family
ID=20407699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98934002T ATE211737T1 (de) | 1997-07-09 | 1998-06-25 | Tricyclisch substituierte 2,4-dithi(oxo)- pyrimidin-5-yl-verbindungen als p2- purinoceptor- antagonisten |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6107297A (de) |
| EP (1) | EP0996617B1 (de) |
| JP (1) | JP2001509506A (de) |
| AT (1) | ATE211737T1 (de) |
| AU (1) | AU8361198A (de) |
| DE (1) | DE69803458T2 (de) |
| DK (1) | DK0996617T3 (de) |
| ES (1) | ES2171300T3 (de) |
| PT (1) | PT996617E (de) |
| SE (1) | SE9702651D0 (de) |
| WO (1) | WO1999002501A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1042320B1 (de) * | 1997-11-21 | 2002-02-13 | AstraZeneca UK Limited | Neue verbindungen, welche antagonisten sind für p2-purinorezeptor 7-transmembran (tm) g-protein gekoppelte rezeptoren |
| IL159058A0 (en) * | 2001-06-12 | 2004-05-12 | Neurogen Corp | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators |
| AUPS160602A0 (en) | 2002-04-08 | 2002-05-16 | University Of Queensland, The | Therapeutic method |
| US7179481B2 (en) * | 2002-09-19 | 2007-02-20 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
| AU2002952086A0 (en) * | 2002-10-16 | 2002-11-07 | The University Of Queensland | Treatment of osteoarthritis |
| US7056889B2 (en) | 2002-12-16 | 2006-06-06 | Kimberly-Clark, Worldwide, Inc. | Compounds that bind P2Y2 or P2Y1 receptors |
| US7098189B2 (en) * | 2002-12-16 | 2006-08-29 | Kimberly-Clark Worldwide, Inc. | Wound and skin care compositions |
| JP4800216B2 (ja) * | 2003-10-24 | 2011-10-26 | エグゼリクシス， インコーポレイテッド | ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法 |
| US7485666B2 (en) * | 2004-06-17 | 2009-02-03 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
| RS53599B1 (sr) | 2005-05-10 | 2015-02-27 | Intermune, Inc. | Piridon derivati za modulaciju stresom aktiviranog sistema proteinskih kinaza |
| JP4431099B2 (ja) | 2005-09-06 | 2010-03-10 | 富士通株式会社 | 波長変換方式、光集積素子及び波長変換方法 |
| JP5188583B2 (ja) | 2008-01-04 | 2013-04-24 | エルジー・ライフ・サイエンシーズ・リミテッド | 細胞、組織及び臓器保存効果を有するインドール及びインダゾール誘導体 |
| JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン， インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
| US9040516B2 (en) | 2011-08-01 | 2015-05-26 | Sumitomo Dainippon Pharma Co., Ltd. | Uracil derivative and use thereof for medical purposes |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CN106459042B (zh) | 2014-04-02 | 2019-06-28 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
| CN104292267A (zh) * | 2014-09-11 | 2015-01-21 | 北京诺泓医药科技有限公司 | 1-羟基-2-(咪唑并[1,2-a]吡啶-3-基)乙烷-1,1-双膦酸的制备方法 |
| CN119486740A (zh) | 2022-04-29 | 2025-02-18 | 德国癌症研究公共权益基金会 | P2ry2活性调节剂 |
-
1997
- 1997-07-09 SE SE9702651A patent/SE9702651D0/xx unknown
-
1998
- 1998-06-25 WO PCT/SE1998/001240 patent/WO1999002501A1/en not_active Ceased
- 1998-06-25 DK DK98934002T patent/DK0996617T3/da active
- 1998-06-25 ES ES98934002T patent/ES2171300T3/es not_active Expired - Lifetime
- 1998-06-25 PT PT98934002T patent/PT996617E/pt unknown
- 1998-06-25 DE DE69803458T patent/DE69803458T2/de not_active Expired - Fee Related
- 1998-06-25 AU AU83611/98A patent/AU8361198A/en not_active Abandoned
- 1998-06-25 EP EP98934002A patent/EP0996617B1/de not_active Expired - Lifetime
- 1998-06-25 JP JP2000502029A patent/JP2001509506A/ja active Pending
- 1998-06-25 AT AT98934002T patent/ATE211737T1/de not_active IP Right Cessation
- 1998-06-25 US US09/155,612 patent/US6107297A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2171300T3 (es) | 2002-09-01 |
| AU8361198A (en) | 1999-02-08 |
| EP0996617B1 (de) | 2002-01-09 |
| DE69803458D1 (de) | 2002-02-28 |
| DK0996617T3 (da) | 2002-04-29 |
| WO1999002501A1 (en) | 1999-01-21 |
| DE69803458T2 (de) | 2002-09-12 |
| EP0996617A1 (de) | 2000-05-03 |
| SE9702651D0 (sv) | 1997-07-09 |
| US6107297A (en) | 2000-08-22 |
| PT996617E (pt) | 2002-06-28 |
| JP2001509506A (ja) | 2001-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE211737T1 (de) | Tricyclisch substituierte 2,4-dithi(oxo)- pyrimidin-5-yl-verbindungen als p2- purinoceptor- antagonisten | |
| TR200101155T2 (tr) | 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III | |
| DE60012040D1 (de) | Trizyklische 1-benzylpyrazol-3-carbonsäurederivate als cannabinoidrezeptorantagonisten | |
| TR200101398T2 (tr) | Pirolidin türevleri-CCR-3 reseptörü antagonistleri. | |
| DE69532162D1 (de) | Cannabinoid-rezeptor-antagonisten | |
| DE60132017D1 (de) | Neue benzazepine und ähnliche heterocyclische derivate,die als orexin rezeptor antagonisten geeignet sind | |
| ES2158813A1 (es) | Sales cuaternarias de piperidina antagonistas del receptor ccr-3 | |
| AR002268A1 (es) | Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas. | |
| ES2182309T3 (es) | Composiciones topicas. | |
| SE9702002D0 (sv) | Novel compounds | |
| DE69333108D1 (de) | Benzodiazepin derivate verwendbar als cck-rezeptoren antagonisten | |
| ATE227276T1 (de) | Neue pyrimidinderivate | |
| EP1100497A4 (de) | Heterocyclyl sulphonamid derivate | |
| DE50008020D1 (de) | Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten | |
| NO963331L (no) | 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister | |
| DK1042320T3 (da) | Nye forbindelser, som er P2-purinoceptor-7-transmembran (TM) G-proteinkoblede receptorantagonister | |
| ATE466862T1 (de) | Sigma-2 rezeptoren als biomarkierer der tumorzellenproliferation | |
| BG102229A (en) | Endothelium receptor antagonists | |
| TR199901380A2 (xx) | Di-ya da triazo-spiro$4,5] dekan t�revleri | |
| NO20000654L (no) | 1,3-dioksolo/4.5-H/2.3/Benzodiazepinderivater som AMPA/kainareseptorinhibitorer | |
| DE69526738D1 (de) | Endothelin-rezeptor-antagonisten | |
| ATE168681T1 (de) | 3-phenylureido-1,5-benzodiazepin-dione verwendbar als gastrin- oder cck antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |